BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Continuous treatment versus fixed duration therapy: Using real-world evidence to...
Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin
Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma ( Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin )
23 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
23 Sep 2019
Evaluating treatment options for acute myeloid leukaemia
Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA
Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
Recent advances in smouldering and relapsed or refractory multiple myeloma
Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA
Recent advances in smouldering and relapsed or refractory multiple myeloma ( Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA )
26 Jul 2019
Use of platform studies for the evaluation of innovative combinations in solid t...
Dr Elizabeth Pease - AstraZeneca, UK
Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies ( Dr Elizabeth Pease - AstraZeneca, UK )
10 Jul 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Chemotherapy-free strategies in treating leukaemia
Prof Robin Foa - University of Rome, Rome, Italy
Chemotherapy-free strategies in treating leukaemia ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-posi...
Prof Robin Foa - University of Rome, Rome, Italy
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )
20 Jun 2019
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
Prof Max Topp - University of Würzburg, Würzburg, Germany
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )
20 Jun 2019
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-...
Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
20 Jun 2019
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with...
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )
20 Jun 2019